At Montreal Children's Hospital, medical technologist Dimitra Sklavenitis had a name for the plastic coil strapped to a child's arm: a “superhero watch.” A hospital profile published in March 2018 followed her and colleague Nadine Boudreau through their work, including collecting sweat for cystic fibrosis testing. The small coil made an unfamiliar procedure easier to describe. What it collected would become evidence about an invisible process inside the skin.[1]

The sweat chloride test asks how much chloride remains in that fluid. Its usefulness depends on a distinction that is easy to miss: producing sweat and recovering salt from sweat are separate jobs. In cystic fibrosis, impaired recovery leaves a chemical signature at the surface.[5]

The journey before the sample

An eccrine sweat gland has two important parts: a secretory coil, which produces fluid, and a duct, which carries it toward the skin. The fluid starts with a salt concentration broadly comparable to that of blood plasma. During its passage, the duct reabsorbs sodium and chloride. Because the duct has low permeability to water, removing salt makes the remaining sweat more dilute.[4]

CFTR, the protein affected in cystic fibrosis, provides a channel through which chloride can move. Sodium has its own route, the epithelial sodium channel, or ENaC. These channels coordinate salt absorption. When CFTR function is impaired, the duct cannot recover salt normally, and more reaches the skin.[4]

This explains how a gland can reveal disease without being blocked by mucus. The sample records what happened while fluid passed through a salt-reabsorbing duct. A high chloride concentration can therefore expose a functional defect that is present before a child's respiratory symptoms have made the diagnosis obvious.[4][7]

Finding the failure in the duct

In May 1983, Paul Quinton and Jan Bijman reported measurements from sweat glands in eight people with cystic fibrosis and seven volunteers without it. Electrical measurements helped them investigate how charged particles moved across the gland. Their calculated rates of sodium and chloride reabsorption were both lower in the cystic fibrosis group, with chloride absorption more markedly reduced.[5]

In the subset studied for sweat output, secretion rates did not differ significantly between groups. That finding supported an explanation centered on impaired recovery of salt, rather than simply greater production of fluid. The study was small and physiological: it investigated a mechanism, not a diagnostic test's accuracy in an entire population.[5]

The clinical test had already been operating for decades. In March 1959, Lewis Gibson and Robert Cooke published their method using pilocarpine iontophoresis to obtain sweat for electrolyte measurement. Diagnosis did not have to wait for the later account of the transport defect.[3]

Collecting a trustworthy drop

In the procedure described by the Cystic Fibrosis Foundation, pilocarpine and a small electrical current stimulate a patch of skin on an arm or leg. Stimulation lasts about five minutes. The sweat is then collected on gauze, filter paper, or in a plastic coil, and sent for laboratory analysis. There is no needle collecting fluid from inside the gland.[2]

The laboratory needs an adequate specimen. Foundation guidance specifies at least 15 microliters for a Macroduct coil, or 75 milligrams for its specified gauze or filter-paper method. It also requires collection practices that limit evaporation and contamination. Evaporation can concentrate what remains; contamination can add material that did not come from the sweat being measured.[6]

An insufficient sample cannot provide a result. Some infants need the procedure repeated because their first collection produces too little fluid. “Not enough sweat” describes an unsuccessful collection, not a reassuring chloride measurement.[2]

The measurement itself also matters. The Foundation's guidance excludes sweat conductivity as a diagnostic substitute for quantitative chloride analysis. Measuring how readily the sample conducts electricity does not provide the required chloride measurement.[6]

A concentration needs a clinical context

The Foundation's 2017 diagnostic guidance, reviewed in July 2025, interprets sweat chloride alongside a positive newborn screen, suggestive symptoms, or family history. A value of 60 mmol/L or higher can establish the diagnosis in that setting. A value below 30 mmol/L makes cystic fibrosis unlikely, although supporting clinical or genetic evidence can still warrant investigation.[7]

The 30–59 mmol/L interval preserves uncertainty. Someone with suggestive findings and intermediate results on two occasions may have cystic fibrosis; extended genetic analysis or specialist tests of CFTR function may help resolve the diagnosis. An intermediate result does not measure a fraction of the disease.[7]

Other conditions can also raise sweat chloride. Positive tests require confirmation on another date or through an independent diagnostic method, such as genetic testing.[6] The clinician reconciles the laboratory result with the reason testing began.

The plastic coil collects the endpoint of a much smaller journey. Its value comes from making salt transport measurable, provided the specimen is sufficient and the result is interpreted within its limits. For a family waiting for an answer, repeating a collection or investigating an intermediate value is part of reaching a dependable diagnosis.

Sources

1. Montreal Children's Hospital, “A day in the life of …two medical technologists!” 5 March 2018; reported clinical scene and photograph of Dimitra Sklavenitis and Nadine Boudreau.
2. Cystic Fibrosis Foundation, “Sweat Test”; patient explanation of stimulation, collection, laboratory analysis, and repeat testing after an insufficient sample.
3. Lewis E. Gibson and Robert E. Cooke, original report introducing pilocarpine iontophoresis for sweat electrolyte testing, Pediatrics 23(3):545–549, March 1959.
4. M. M. Reddy and M. J. Stutts, “Status of Fluid and Electrolyte Absorption in Cystic Fibrosis,” Cold Spring Harbor Perspectives in Medicine 3:a009555, 2013; physiological review, especially sweat-duct salt absorption.
5. Paul M. Quinton and Jan Bijman, “Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis,” New England Journal of Medicine 308:1185–1189, 19 May 1983; original human physiological study.
6. Cystic Fibrosis Foundation, “Sweat Test Clinical Care Guidelines”; collection quantities, analytical requirements, and confirmation, based on the 2007 guideline and subsequent diagnostic guidance; reviewed July 2025.
7. Cystic Fibrosis Foundation, “CF Diagnosis Clinical Care Guidelines,” February 2017, reviewed July 2025; clinical context, chloride thresholds, and investigation of intermediate results.